Parmax Pharma Ltd: Control Shifts as Promoters Sell 30.80% Stake

30.80% promoter stake sold; Reclassification of promoters underway.

Reader Takeaway: New promoters take charge; Regulatory compliance in focus.

What just happened

Parmax Pharma Ltd has informed the stock exchanges about a significant change in its control and a reclassification of its promoters. This follows a Share Purchase Agreement (SPA) executed on June 8, 2026, where a group of acquirers and Persons Acting in Concert (PACs) bought 1,152,450 equity shares. This block of shares represents 30.80% of the company's total equity share capital.

The erstwhile promoters selling their stakes are Alkesh Mahasukhlal Gopani (17.92%), Vipul Mahasukhlal Gopani (12.87%), and Pravina Mahasukh Gopani (0.02%).

Why this matters

This transaction signifies a complete change in the ownership structure and management control of Parmax Pharma Ltd. The reclassification of promoters as per SEBI (LODR) Regulations, 2015, is a crucial step that will define the new leadership and governance framework of the company. Shareholders should monitor how the new management steers the company forward.

The backstory

The filing indicates a formal process of promoter reclassification under SEBI regulations. This is a standard procedure when a substantial stake changes hands, ensuring transparency and compliance with corporate governance norms.

What changes now

Following the completion of an open offer (details not provided in the filing) and the share transfer, the acquirers, Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with PACs Hiren Pravin Doshi and Umang Alkesh Gosalia, will be classified as the new Promoters. Other PACs will be part of the Promoter Group, while the original promoters move to the public category.

Regulatory Compliance

Parmax Pharma has obtained necessary undertakings from the outgoing promoters, confirming they meet SEBI's criteria for reclassification. These include not holding more than 10% voting rights, not exercising control, not having special rights, and not being on the board or KMP. The company also confirmed no suspended trading and no outstanding dues to regulatory bodies.

Context metrics (time-bound)

The Share Purchase Agreement was entered into on June 8, 2026.

What to track next

Investors will be keen to see the outcome of the open offer and any subsequent strategic announcements from the new promoter group regarding the company's future direction and operations.